Europe Biopharmaceuticals Market Outlook, 2029

The Europe Biopharmaceuticals Market is projected to reach a robust USD 310.2 billion by 2028, driven by focus in Bio similars.

According to publisher, Here is a Continent Fostering Innovation in Biopharmaceuticals Market. It is Europe. The European biopharmaceuticals market is a thriving hub of innovation, boasting a strong presence of research institutions and pharmaceutical giants. The market size is projected to reach a robust USD 310.2 billion by 2028, reflecting a steady CAGR of 7.8%. Here's a concise analysis of this vital healthcare sector: Market Insights

What's Inside a Bonafide Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

Aging Population: Europe's aging population fuels demand for biopharmaceuticals that treat chronic diseases like Alzheimer's and cancer. Focus on Biosimilars: Europe is a pioneer in biosimilars, which are more affordable alternatives to complex biological drugs. This improves access to treatment and reduces healthcare costs. (Ex: Biosimilar versions of Epoetin alfa for anemia treatment) Market Dynamics

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant

Drivers: Government Support: Governments in Europe actively support research and development (R&D) in biopharmaceuticals, fostering innovation and drug discovery. Growing Adoption of Personalized Medicine: Tailoring treatments to individual patients' genetic makeup is gaining traction, creating a need for specialized biopharmaceuticals.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval

Restraints: Strict Regulatory Environment: Stringent regulations, while ensuring safety, can delay drug approvals and impact market access for new biopharmaceuticals. Patent Expiry: The expiry of patents on blockbuster drugs can lead to price pressures and competition from generics. Market Segments Product Type: Monoclonal Antibodies: These targeted therapies are used to treat various cancers and autoimmune diseases. (Ex: Rituximab for Non-Hodgkin's lymphoma) Vaccines: A crucial segment with ongoing development of vaccines for new and emerging infectious diseases. (Ex: Continued development of COVID-19 vaccines) Gene Therapies: A rapidly evolving field with the potential to treat genetic disorders. (Ex: Kymriah for acute lymphoblastic leukemia) Application: Oncology: The largest segment due to the high prevalence of cancer and ongoing development of targeted therapies. Immunology: A rapidly growing segment with treatments for autoimmune diseases and inflammatory conditions. Neurology: Focus on neurodegenerative diseases like Alzheimer's and Parkinson's. Regional Analysis Germany Leads the Way: Germany is the European leader due to its strong research base, pharmaceutical giants like Bayer and Merck, and a supportive government environment. Other Key Players: France, the UK, Switzerland, and Italy are also major players with significant R&D capabilities and biopharmaceutical production facilities. Key Developments Precision Medicine Initiatives: European countries are investing heavily in precision medicine initiatives, aiming to personalize treatments and improve patient outcomes. Rise of Biosimilar Manufacturing: Biosimilar production is increasing in Europe, providing cost-effective treatment options and fostering competition within the market. Focus on Biologic Contract Manufacturing: Contract manufacturing organizations (CMOs) are playing a growing role, helping biopharmaceutical companies develop and manufacture drugs efficiently. Competitive Landscape A Mix of Big Pharma and Biotech Startups: Major pharmaceutical companies like Roche and Novartis compete alongside innovative biotech startups developing next-generation biopharmaceuticals. Open Innovation Strategies: Collaboration between pharmaceutical companies, research institutions, and startups is accelerating innovation in the European biopharmaceuticals market. Future Outlook The European biopharmaceuticals market is well-positioned for continued growth, driven by: Advancements in Biotechnology: New technologies like gene editing and gene therapy hold immense promise for future treatments. Focus on Value-Based Pricing: Emphasis on the economic value a drug brings to the healthcare system, alongside its cost, will influence pricing strategies. Aging Population Needs: The market will adapt to cater to the specific needs of an aging population, with a focus on chronic disease management and preventative healthcare. Europe's strong scientific base, supportive regulatory environment, and focus on innovation will solidify its position as a global leader in the biopharmaceuticals market.

Table of Contents

  • 1 Introduction 9
  • 1.1 Industry Definition and Research Scope 9
  • 1.1.1 Industry Definition 9
  • 1.1.2 Research Scope 10
  • 1.2 Research Methodology 13
  • 1.2.1 Overview of Market Research Methodology 13
  • 1.2.2 Market Assumption 14
  • 1.2.3 Secondary Data 14
  • 1.2.4 Primary Data 14
  • 1.2.5 Data Filtration and Model Design 15
  • 1.2.6 Market Size/Share Estimation 16
  • 1.2.7 Research Limitations 17
  • 1.3 Executive Summary 18
  • 2 Market Overview and Dynamics 21
  • 2.1 Market Size and Forecast 21
  • 2.1.1 Impact of COVID-19 on World Economy 22
  • 2.1.2 Impact of COVID-19 on the Market 26
  • 2.1.3 Impact of Russia-Ukraine Conflict 28
  • 2.1.4 Impact of Israel-Palestine War 30
  • 2.2 Major Growth Drivers 31
  • 2.3 Market Restraints and Challenges 40
  • 2.4 Emerging Opportunities and Market Trends 43
  • 2.5 Porter’s Fiver Forces Analysis 47
  • 3 Segmentation of Europe Market by Product Type 51
  • 3.1 Market Overview by Product Type 51
  • 3.2 Monoclonal Antibodies 53
  • 3.2.1 Anti-cancer Monoclonal Antibodies 54
  • 3.2.2 Anti-inflammatory Monoclonal Antibodies 55
  • 3.2.3 Other Monoclonal Antibodies 56
  • 3.3 Recombinant Growth Factors 57
  • 3.3.1 Erythropoietin 58
  • 3.3.2 Granulocyte Colony Stimulating Factor 59
  • 3.4 Purified Proteins 60
  • 3.4.1 Leukemia Inhibitory Factor (LIF) 61
  • 3.4.2 P53 Protein 62
  • 3.4.3 P38 Protein 63
  • 3.4.4 Other Purified Proteins 64
  • 3.5 Recombinant Proteins 65
  • 3.5.1 Serum Albumin 66
  • 3.5.2 Amyloid Protein 67
  • 3.5.3 Defensin 68
  • 3.5.4 Transferrin 69
  • 3.6 Recombinant Hormones 70
  • 3.6.1 Recombinant Human Growth Hormones 71
  • 3.6.2 Recombinant Insulin 73
  • 3.6.3 Other Recombinant Hormones 74
  • 3.7 Vaccines 75
  • 3.7.1 Recombinant Vaccines 76
  • 3.7.2 Conventional Vaccines 78
  • 3.8 Recombinant Enzymes 79
  • 3.8.1 Enterokinase 80
  • 3.8.2 Cyclase 81
  • 3.8.3 Caspase 82
  • 3.8.4 Cathepsin 83
  • 3.9 Cell and Gene Therapies 84
  • 3.9.1 Allogenic Products 85
  • 3.9.2 Autologous Products 86
  • 3.9.3 Acellular Products 87
  • 3.10 Synthetic Immunomodulators 88
  • 3.11 Other Product Types 89
  • 3.11.1 Blood Factors 90
  • 3.11.2 Other Products 91
  • 4 Segmentation of Europe Market by Testing Service 92
  • 4.1 Market Overview by Testing Service 92
  • 4.2 Laboratory Testing 94
  • 4.3 Custom Testing/Customer Proprietary Testing 95
  • 4.4 Compendial and Multi Compendial Laboratory Testing 96
  • 5 Segmentation of Europe Market by Raw Material 97
  • 5.1 Market Overview by Raw Material 97
  • 5.2 Formulation Excipients 99
  • 5.3 Active Pharmaceutical Ingredients (API) 100
  • 5.4 Other Materials 101
  • 6 Segmentation of Europe Market by Classification 102
  • 6.1 Market Overview by Classification 102
  • 6.2 Innovative Biopharmaceuticals 104
  • 6.3 Biogenerics and Biosimilars 105
  • 7 Segmentation of Europe Market by Therapeutic Area 106
  • 7.1 Market Overview by Therapeutic Area 106
  • 7.2 Oncology 108
  • 7.3 Inflammatory and Infectious Diseases 109
  • 7.4 Autoimmune Disorders 110
  • 7.5 Metabolic Disorders 111
  • 7.6 Hormonal Disorders 112
  • 7.7 Cardiovascular Diseases 113
  • 7.8 Neurological Diseases 114
  • 7.9 Other Therapeutic Areas 115
  • 8 European Market 2023-2033 by Country 116
  • 8.1 Overview of European Market 116
  • 8.2 Germany 119
  • 8.3 U.K. 121
  • 8.4 France 123
  • 8.5 Spain 125
  • 8.6 Italy 127
  • 8.7 Netherlands 129
  • 8.8 Rest of European Market 131
  • 9 Competitive Landscape 133
  • 9.1 Overview of Key Vendors 133
  • 9.2 New Product Launch, Partnership, Investment, and M&A 137
  • 9.3 Company Profiles 138
  • Abbott Laboratories 138
  • Amgen Inc. 140
  • Astrazeneca PLC 141
  • Bayer AG 142
  • Biogen Inc. 143
  • Bristol-myers Squibb Company (BMS) 144
  • Eli Lilly and Company 145
  • F. Hoffmann-La Roche Ltd. 146
  • Glaxosmithkline PLC 147
  • Johnson & Johnson 148
  • Merck & Co. Inc. 149
  • Novartis Ag 150
  • Novo Nordisk As 151
  • Pfizer Inc. 152
  • Sanofi Sa 153
  • Sharp Packaging Services 154
  • Sun Pharmaceutical Industries Ltd. 155
  • Takeda Pharmaceutical Company Limited 156
  • Thermo Fisher Scientific Inc. 157
  • Vertex Pharmaceuticals 158
  • WuXi AppTec 159
  • RELATED REPORTS 160



Table 1. Snapshot of Europe Biopharmaceuticals Market in Balanced Perspective, 2023-2033 19
Table 2. World Economic Outlook, 2024-2036 23
Table 3. World Economic Outlook, 2022-2024 25
Table 4. Scenarios for Economic Impact of Ukraine Crisis 29
Table 5. Scenarios for Economic Impact of Israel-Palestine War 30
Table 6. World Health Spending by Region, $ bn, 2013-2020 35
Table 7. Total Number of Registered Clinical Studies Worldwide, 2010-2021 36
Table 8. Worldwide Number of New Cancer by Type, 2020 37
Table 9. Main Product Trends and Market Opportunities in Europe Biopharmaceuticals Market 43
Table 10. Europe Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 51
Table 11. Europe Biopharmaceuticals Market: Monoclonal Antibodies by Type, 2023-2033, $ mn 53
Table 12. Europe Biopharmaceuticals Market: Recombinant Growth Factor by Type, 2023-2033, $ mn 57
Table 13. Europe Biopharmaceuticals Market: Purified Proteins by Type, 2023-2033, $ mn 60
Table 14. Europe Biopharmaceuticals Market: Recombinant Proteins by Type, 2023-2033, $ mn 65
Table 15. Europe Biopharmaceuticals Market: Recombinant Hormones by Type, 2023-2033, $ mn 70
Table 16. Selected Drugs for COVID-19 Treatment in Development, Nov 2022 72
Table 17. Europe Biopharmaceuticals Market: Vaccines by Type, 2023-2033, $ mn 75
Table 18. Europe Biopharmaceuticals Market: Recombinant Vaccines by Type, 2023-2033, $ mn 77
Table 19. Europe Biopharmaceuticals Market: Conventional Vaccines by Type, 2023-2033, $ mn 78
Table 20. Europe Biopharmaceuticals Market: Recombinant Enzymes by Type, 2023-2033, $ mn 79
Table 21. Europe Biopharmaceuticals Market: Cell and Gene Therapies by Type, 2023-2033, $ mn 84
Table 22. Europe Biopharmaceuticals Market: Other Product Types by Type, 2023-2033, $ mn 89
Table 23. Europe Biopharmaceuticals Market by Testing Service, 2023-2033, $ mn 92
Table 24. Europe Biopharmaceuticals Market by Raw Material, 2023-2033, $ mn 97
Table 25. Europe Biopharmaceuticals Market by Classification, 2023-2033, $ mn 102
Table 26. Europe Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 106
Table 27. Europe Biopharmaceuticals Market by Country, 2023-2033, $ mn 118
Table 28. Germany Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 120
Table 29. Germany Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 120
Table 30. U.K. Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 122
Table 31. U.K. Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 122
Table 32. France Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 124
Table 33. France Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 124
Table 34. Spain Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 126
Table 35. Spain Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 126
Table 36. Italy Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 128
Table 37. Italy Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 128
Table 38. Netherlands Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 130
Table 39. Netherlands Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 130
Table 40. Biopharmaceuticals Market in Rest of Europe by Country, 2023-2033, $ mn 132
Table 41. Abbott Laboratories: Company Snapshot 138
Table 42. Abbott Laboratories: Business Segmentation 139
Table 43. Abbott Laboratories: Product Portfolio 139



Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2023-2033 18
Figure 4. Europe Biopharmaceuticals Market, 2023-2033, $ mn 21
Figure 5. Impact of COVID-19 on Business 26
Figure 6. Primary Drivers and Impact Factors of Europe Biopharmaceuticals Market 31
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 34
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 34
Figure 9. Worldwide Novel Active Substances (NASs) Launches by Therapeutic Area, 2013-2022 35
Figure 10. Primary Restraints and Impact Factors of Europe Biopharmaceuticals Market 40
Figure 11. Investment Opportunity Analysis 44
Figure 12. Porter’s Fiver Forces Analysis of Europe Biopharmaceuticals Market 47
Figure 13. Breakdown of Europe Biopharmaceuticals Market by Product Type, 2023-2033, % of Revenue 52
Figure 14. Europe Addressable Market Cap in 2024-2033 by Product Type, Value ($ mn) and Share (%) 52
Figure 15. Europe Biopharmaceuticals Market by Product Type: Monoclonal Antibodies, 2023-2033, $ mn 53
Figure 16. Europe Biopharmaceuticals Market by Monoclonal Antibodies: Anti-cancer Monoclonal Antibodies, 2023-2033, $ mn 54
Figure 17. Europe Biopharmaceuticals Market by Monoclonal Antibodies: Anti-inflammatory Monoclonal Antibodies, 2023-2033, $ mn 55
Figure 18. Europe Biopharmaceuticals Market by Monoclonal Antibodies: Other Monoclonal Antibodies, 2023-2033, $ mn 56
Figure 19. Europe Biopharmaceuticals Market by Product Type: Recombinant Growth Factors, 2023-2033, $ mn 57
Figure 20. Europe Biopharmaceuticals Market by Recombinant Growth Factor: Erythropoietin, 2023-2033, $ mn 58
Figure 21. Europe Biopharmaceuticals Market by Recombinant Growth Factor: Granulocyte Colony Stimulating Factor, 2023-2033, $ mn 59
Figure 22. Europe Biopharmaceuticals Market by Product Type: Purified Proteins, 2023-2033, $ mn 60
Figure 23. Europe Biopharmaceuticals Market by Purified Proteins: Leukemia Inhibitory Factor (LIF), 2023-2033, $ mn 61
Figure 24. Europe Biopharmaceuticals Market by Purified Proteins: P53 Protein, 2023-2033, $ mn 62
Figure 25. Europe Biopharmaceuticals Market by Purified Proteins: P38 Protein, 2023-2033, $ mn 63
Figure 26. Europe Biopharmaceuticals Market by Purified Proteins: Other Purified Proteins, 2023-2033, $ mn 64
Figure 27. Europe Biopharmaceuticals Market by Product Type: Recombinant Proteins, 2023-2033, $ mn 65
Figure 28. Europe Biopharmaceuticals Market by Recombinant Proteins: Serum Albumin, 2023-2033, $ mn 66
Figure 29. Europe Biopharmaceuticals Market by Recombinant Proteins: Amyloid Protein, 2023-2033, $ mn 67
Figure 30. Europe Biopharmaceuticals Market by Recombinant Proteins: Defensin, 2023-2033, $ mn 68
Figure 31. Europe Biopharmaceuticals Market by Recombinant Proteins: Transferrin, 2023-2033, $ mn 69
Figure 32. Europe Biopharmaceuticals Market by Product Type: Recombinant Hormones, 2023-2033, $ mn 70
Figure 33. Europe Biopharmaceuticals Market by Recombinant Hormones: Recombinant Human Growth Hormones, 2023-2033, $ mn 71
Figure 34. Europe Biopharmaceuticals Market by Recombinant Hormones: Recombinant Insulin, 2023-2033, $ mn 73
Figure 35. Europe Biopharmaceuticals Market by Recombinant Hormones: Other Recombinant Hormones, 2023-2033, $ mn 74
Figure 36. Europe Biopharmaceuticals Market by Product Type: Vaccines, 2023-2033, $ mn 75
Figure 37. Europe Biopharmaceuticals Market by Vaccines: Recombinant Vaccines, 2023-2033, $ mn 76
Figure 38. Europe Biopharmaceuticals Market by Vaccines: Conventional Vaccines, 2023-2033, $ mn 78
Figure 39. Europe Biopharmaceuticals Market by Product Type: Recombinant Enzymes, 2023-2033, $ mn 79
Figure 40. Europe Biopharmaceuticals Market by Recombinant Enzymes: Enterokinase, 2023-2033, $ mn 80
Figure 41. Europe Biopharmaceuticals Market by Recombinant Enzymes: Cyclase, 2023-2033, $ mn 81
Figure 42. Europe Biopharmaceuticals Market by Recombinant Enzymes: Caspase, 2023-2033, $ mn 82
Figure 43. Europe Biopharmaceuticals Market by Recombinant Enzymes: Cathepsin, 2023-2033, $ mn 83
Figure 44. Europe Biopharmaceuticals Market by Product Type: Cell and Gene Therapies, 2023-2033, $ mn 84
Figure 45. Europe Biopharmaceuticals Market by Cell and Gene Therapies: Allogenic Products, 2023-2033, $ mn 85
Figure 46. Europe Biopharmaceuticals Market by Cell and Gene Therapies: Autologous Products, 2023-2033, $ mn 86
Figure 47. Europe Biopharmaceuticals Market by Cell and Gene Therapies: Acellular Products, 2023-2033, $ mn 87
Figure 48. Europe Biopharmaceuticals Market by Product Type: Synthetic Immunomodulators, 2023-2033, $ mn 88
Figure 49. Europe Biopharmaceuticals Market by Product Type: Other Product Types, 2023-2033, $ mn 89
Figure 50. Europe Biopharmaceuticals Market by Other Product Types: Blood Factors, 2023-2033, $ mn 90
Figure 51. Europe Biopharmaceuticals Market by Other Product Types: Other Products, 2023-2033, $ mn 91
Figure 52. Breakdown of Europe Biopharmaceuticals Market by Testing Service, 2023-2033, % of Sales Revenue 93
Figure 53. Europe Addressable Market Cap in 2024-2033 by Testing Service, Value ($ mn) and Share (%) 93
Figure 54. Europe Biopharmaceuticals Market by Testing Service: Laboratory Testing, 2023-2033, $ mn 94
Figure 55. Europe Biopharmaceuticals Market by Testing Service: Custom Testing/Customer Proprietary Testing, 2023-2033, $ mn 95
Figure 56. Europe Biopharmaceuticals Market by Testing Service: Compendial and Multi Compendial Laboratory Testing, 2023-2033, $ mn 96
Figure 57. Breakdown of Europe Biopharmaceuticals Market by Raw Material, 2023-2033, % of Sales Revenue 98
Figure 58. Europe Addressable Market Cap in 2024-2033 by Raw Material, Value ($ mn) and Share (%) 98
Figure 59. Europe Biopharmaceuticals Market by Raw Material: Formulation Excipients, 2023-2033, $ mn 99
Figure 60. Europe Biopharmaceuticals Market by Raw Material: Active Pharmaceutical Ingredients (API), 2023-2033, $ mn 100
Figure 61. Europe Biopharmaceuticals Market by Raw Material: Other Materials, 2023-2033, $ mn 101
Figure 62. Breakdown of Europe Biopharmaceuticals Market by Classification, 2023-2033, % of Revenue 103
Figure 63. Europe Addressable Market Cap in 2024-2033 by Classification, Value ($ mn) and Share (%) 103
Figure 64. Europe Biopharmaceuticals Market by Classification: Innovative Biopharmaceuticals, 2023-2033, $ mn 104
Figure 65. Europe Biopharmaceuticals Market by Classification: Biogenerics and Biosimilars, 2023-2033, $ mn 105
Figure 66. Breakdown of Europe Biopharmaceuticals Market by Therapeutic Area, 2023-2033, % of Revenue 107
Figure 67. Europe Addressable Market Cap in 2024-2033 by Therapeutic Area, Value ($ mn) and Share (%) 107
Figure 68. Europe Biopharmaceuticals Market by Therapeutic Area: Oncology, 2023-2033, $ mn 108
Figure 69. Europe Biopharmaceuticals Market by Therapeutic Area: Inflammatory and Infectious Diseases, 2023-2033, $ mn 109
Figure 70. Europe Biopharmaceuticals Market by Therapeutic Area: Autoimmune Disorders, 2023-2033, $ mn 110
Figure 71. Europe Biopharmaceuticals Market by Therapeutic Area: Metabolic Disorders, 2023-2033, $ mn 111
Figure 72. Europe Biopharmaceuticals Market by Therapeutic Area: Hormonal Disorders, 2023-2033, $ mn 112
Figure 73. Europe Biopharmaceuticals Market by Therapeutic Area: Cardiovascular Diseases, 2023-2033, $ mn 113
Figure 74. Europe Biopharmaceuticals Market by Therapeutic Area: Neurological Diseases, 2023-2033, $ mn 114
Figure 75. Europe Biopharmaceuticals Market by Therapeutic Area: Other Therapeutic Areas, 2023-2033, $ mn 115
Figure 76. Breakdown of European Biopharmaceuticals Market by Country, 2023 and 2033, % of Revenue 117
Figure 77. Contribution to Europe 2024-2033 Cumulative Market by Country, Value ($ mn) and Share (%) 118
Figure 78. Biopharmaceuticals Market in Germany, 2023-2033, $ mn 119
Figure 79. Biopharmaceuticals Market in U.K., 2023-2033, $ mn 121
Figure 80. Biopharmaceuticals Market in France, 2023-2033, $ mn 123
Figure 81. Biopharmaceuticals Market in Spain, 2023-2033, $ mn 125
Figure 82. Biopharmaceuticals Market in Italy, 2023-2033, $ mn 127
Figure 83. Biopharmaceuticals Market in Netherlands, 2023-2033, $ mn 129
Figure 84. Biopharmaceuticals Market in Rest of Europe, 2023-2033, $ mn 131
Figure 85. Growth Stage of Europe Biopharmaceuticals Industry over the Forecast Period 133
Figure 86. Worldwide Top Ten Best-selling Biotech Drugs in 2022, $ bn 135
Logo

Europe Biopharmaceuticals Market Outlook, 2029

Contact usWe are friendly and approachable, give us a call.